- [Resource Hub](/)
- [Resource](/?resource-type=poster#library)
- Quantitative analysis of HER2, HER3, and γH2AX expression on circulating tumor cells for pharmacodynamic measurement in clinical trials

# Quantitative analysis of HER2, HER3, and γH2AX expression on circulating tumor cells for pharmacodynamic measurement in clinical trials

Repeat tissue biopsies are often impractical for tracking how a therapy is working, so this AACR 2025 poster develops circulating tumor cell assays that quantify HER2, HER3, and γH2AX protein expression from a blood draw for pharmacodynamic measurement in clinical trials.

Presented by RareCyte.

Read or download to see:

- Three single-biomarker CTC assays — one each for HER2, HER3, and γH2AX — were analytically validated on cell lines spiked into healthy donor blood. On these model CTCs, sensitivity was 100% for HER2, 88.1% for HER3, and 91.9% for γH2AX, with specificity of 97.7%, 96.0%, and 96.7% respectively — analytical figures on spiked control cells, not clinical performance in patients.

- Every assay proved reproducible, with all coefficients of variation under 20%. Inter-stainer-run precision ranged from 8.0% (HER2) to 18.4% (γH2AX) across three independent stainer runs, and intra-run repeatability held within 3.8–12.1% across five control slides in a single run.

- The HER2 assay was tested on 16 cell lines with a range of HER2 expression, distinguishing the known IHC scores of 0, 1+, 2+, and 3+. All three assays have been deployed in clinical trials as pharmacodynamic biomarkers, and each single-biomarker assay can be extended to a dual readout by adding one custom marker of interest to the same CTC.

[Download poster](https://cdn.sanity.io/files/s3p6uqps/production/43fb6d4a8510166e936d250b3bf172e2f669bfa3.pdf)

Your browser doesn’t support embedded PDFs.
[Download the poster](https://cdn.sanity.io/files/s3p6uqps/production/43fb6d4a8510166e936d250b3bf172e2f669bfa3.pdf) to view it.

[Back to all resources](/#library)
## Related resources
[Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) CyteFinder 2026
### Dr. Pashtoon Kasi on the impact of circulating tumor cells on clinical research
[Watch Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/bf293dca89c166ae45c117d42bec62d06749f553.pdf) CyteFinder 2024
### Real-time monitoring of CTC number, biomarker expression, and kinetics as prognostic and predictive markers in patients with GI malignancies
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/bf293dca89c166ae45c117d42bec62d06749f553.pdf) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC10693413/) CyteFinder Frontiers in Oncology 2023
### Circulating tumor cell enumeration, biomarker analyses, and kinetics in patients with colorectal cancer and other GI malignancies
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC10693413/) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/e35dfc002f133eaedcf9005374c5ce828f4dc193.pdf) CyteFinder 2022
### Validation of increased sample stability using the AccuCyte®-CyteFinder® CTC Platform to improve logistics in global clinical trials
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/e35dfc002f133eaedcf9005374c5ce828f4dc193.pdf) [Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) CyteFinder Journal of Clinical Oncology 2026
### Clinical validation of circulating tumor cell synaptophysin and androgen receptor expression in metastatic prostate cancer phenotypes.
[View Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/691cd6e9b37a23fdd7d358244e8fcbac9fc2738b.pdf) 2026
### Clinical Validation of Circulating Tumor Cell Synaptophysin and Androgen Receptor Expression in Metastatic Prostate Cancer Phenotypes
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/691cd6e9b37a23fdd7d358244e8fcbac9fc2738b.pdf) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) CyteFinder Nature Communications 2026
### Extracellular matrix mediates circulating tumor cell clustering in triple-negative breast cancer metastasis
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) [Publication](https://doi.org/10.1016/j.ejso.2025.111357) CyteFinder European Journal of Surgical Oncology 2026
### Circulating tumor cells predict relapse in head and neck mucosal squamous cell carcinoma
[View Publication](https://doi.org/10.1016/j.ejso.2025.111357) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) CyteFinder Cancer Research Communications 2026
### Surface Marker Identification to Capture Live Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) [Publication](https://doi.org/10.3390/cancers17162717) CyteFinder Cancers 2025
### Comprehensive Longitudinal Linear Mixed Modelling of CTCs Illuminates the Role of Trop2, EpCAM, and CD45 in CTC Clustering and Metastasis
[View Publication](https://doi.org/10.3390/cancers17162717) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12213210/) CyteFinder Clinical Cancer Research 2025
### Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung Cancer
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12213210/) [Publication](https://doi.org/10.1080/07366205.2025.2534299) CyteFinder BioTechniques 2025
### A novel device for buffy coat collection
[View Publication](https://doi.org/10.1080/07366205.2025.2534299)